The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality in high-risk populations. Several therapeutics have been developed to reduce the risk of complications related to COVID-19, hospitalizations, and death. In several studies, nirmatrelvir-ritona...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Obaidi, Mohanad M., Gungor, Ahmet B., Murugapandian, Sangeetha, Thajudeen, Bijin, Mansour, Iyad, Wong, Ryan C., Tanriover, Bekir, Zangeneh, Tirdad T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Clinical Research Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993659/
https://www.ncbi.nlm.nih.gov/pubmed/36898600
http://dx.doi.org/10.1016/j.amjmed.2023.02.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9993659/
https://www.ncbi.nlm.nih.gov/pubmed/36898600
http://dx.doi.org/10.1016/j.amjmed.2023.02.022

Ejemplares similares